Every article, presentation, spotlight, and news item we've tagged to Regenerative Therapies.
Showing 73–96 of 154
Coultreon Biopharma raised $125 million to advance COL-5671, an oral SIK3 inhibitor designed to restore immune balance rather than blunt inflammatory suppression in autoimmune disease. The approach targets a mechanism relevant to chronic immune dysregulation associated with aging, positioning the therapy as a potential bridge between disease treatment and healthspan optimization.
Mayo Clinic and Sana Biotechnology are collaborating to develop SC451, a hypoimmune-modified pancreatic islet cell therapy designed to restore glucose control in type 1 diabetes without requiring ongoing insulin or immunosuppression. The partnership establishes protocols for clinical delivery, patient selection, and monitoring to support Phase 1 trials beginning this year.
Restore Hyper Wellness is promoting NAD supplementation through IV and intramuscular delivery formats, capitalizing on significant year-over-year increases in consumer search interest for NAD-related therapies. The initiative positions NAD precursors and direct NAD administration as tools for cellular energy optimization, though clinical evidence supporting broad longevity claims remains limited.
Cellular senescence—the accumulation of non-dividing cells that secrete inflammatory factors—drives age-related decline in multiple organ systems. Understanding how senescent cells compromise tissue function and identifying interventions that clear or manage their activity offers a direct path to extending both healthspan and lifespan.
Niagen Bioscience secured a US patent protecting intravenous and injectable formulations of nicotinamide riboside (NR), a NAD+ precursor molecule that declines with age and cellular stress. The patent extends protection through 2044 and positions the company to dominate clinical delivery of NAD+ boosters, a market rapidly expanding across wellness clinics.
Mitochondrial stress emerges as a critical mechanism underlying senolytic effectiveness against senescent cells. This finding suggests that the therapeutic benefit of senolytics depends partly on their capacity to induce cellular energy stress, offering a framework for optimizing drug selection and combination strategies in senescence-targeted interventions.
Klotho Neurosciences has developed AI-powered genomics tests that measure biological age through DNA methylation and mRNA analysis of longevity-associated genes. This approach enables more precise stratification in clinical trials for neurodegenerative diseases, reducing confounding variables that arise when chronological and biological age diverge.
Fisetin, a plant-derived senolytic, reverses age-related endothelial dysfunction in aging mice by eliminating senescent endothelial cells and reducing the SASP factor CXCL12, which drives vascular dysfunction through oxidative stress and impaired nitric oxide production. This identifies a mechanistic pathway linking cellular senescence to cardiovascular aging and demonstrates functional recovery through targeted senolytic intervention.
Niagen Bioscience launched Niagen Plus, a telehealth platform delivering prescription-only nicotinamide riboside (Niagen) via at-home subcutaneous injection. The injectable route is positioned to bypass first-pass hepatic metabolism and improve tissue bioavailability compared to oral administration.
The Senotherapeutics Biomarker Consortium establishes standardized biomarkers for identifying and measuring cellular senescence across tissues and populations, enabling translation of senolytic therapies from research to clinical practice. This addresses a critical gap in longevity medicine: the ability to reliably detect senescent cells and track treatment response in living humans.
Senolytic treatment with ABT-263 reduced lung and intestinal inflammation and prevented long-term pulmonary damage in aged mice infected with influenza, though it did not reduce viral replication itself. The findings indicate that pre-existing senescent cells drive inflammatory pathology rather than viral control, suggesting a therapeutic target for improving outcomes in older adults.
Senolytic treatments did not reverse epigenetic signatures associated with cellular senescence, despite reducing senescent cell burden. This finding questions whether DNA methylation changes adequately capture senescence biology and whether current aging biomarkers respond as expected to geroscience interventions.
Dasatinib and quercetin (D+Q), a widely used senolytic combination, impairs oligodendrocyte function and reduces myelination in the brain through endoplasmic reticulum stress, causing morphological changes similar to those seen in multiple sclerosis. This finding indicates that senolytic interventions carry neurological risks that warrant careful evaluation before clinical deployment.
Aging T cells develop senescence characteristics that drive chronic inflammatory skin diseases through dysregulated signaling pathways and secretion of pro-inflammatory factors. Targeting senescent T cells or their signaling cascades offers a mechanism-based approach to achieving sustained remission in conditions like psoriasis and atopic dermatitis.
Rubedo Life Sciences has advanced RLS-1496, a first-in-class GPX4 modulator senolytic, through Phase 1 human trials based on the company's ALEMBIC AI platform for identifying senescent cell vulnerabilities. This represents a shift from repurposed compounds toward precision-targeted senolytics designed to eliminate dysfunctional cells while sparing healthy tissue.
Two conjugated polyunsaturated fatty acids, α-eleostearic acid and its methyl ester, demonstrated senolytic activity in cell cultures and mouse models across multiple tissues without systemic toxicity. The structural features of these compounds—particularly conjugation patterns and double-bond configuration—correlate with their ability to eliminate senescent cells, which accumulate with age and drive inflammatory cascades linked to chronic disease.
Proteomic analysis identified 311 plasma proteins whose expression patterns correlate with both chronological age and disease burden in older adults, representing candidate biomarkers of biological aging. These proteins suggest shared regulatory pathways between aging and chronic disease progression and may enable risk stratification and intervention monitoring.
Mitochondrial dysfunction is increasingly recognized as a central mechanism underlying age-related disease, not merely a feature of rare genetic conditions. The FDA approval of elamipretide (Forzinity) for Barth syndrome represents the first regulatory validation of mitochondria-targeted therapeutics, positioning this class of drugs as potential interventions for common age-related conditions including neurodegeneration and cardiac disease.
Plasma proteomics of Swiss centenarians identified 37 proteins maintaining a younger profile despite advanced age, with pathways implicating immune regulation, metabolic enzyme function, and extracellular matrix stability. These findings establish reproducible molecular signatures of healthy longevity across independent cohorts and suggest specific protein targets for aging intervention.
Telocyte's founder argues that effective longevity intervention requires reversing aging at the cellular level rather than managing age-related diseases incrementally. The company is preparing a telomerase gene therapy trial in dogs, with the thesis that aging results from failed maintenance systems that can be reset rather than from inevitable biological decline.
Moderate hyperoxia induces cellular senescence in developing airway tissue, with lasting consequences for lung function. Three mechanistically distinct interventions—Fucoidan, Dasatinib plus Quercetin, and MitoQ—each mitigate senescence through different pathways, offering potential strategies to prevent hyperoxia-related lung disease in premature infants.
Multiple biotech companies are developing cell-based therapies targeting aging as an underlying condition rather than treating age-related diseases individually. The longevity biotech market is projected to grow from $9.86 billion in 2025 to $29.7 billion by 2034, driven by approaches using encapsulated cells, gene therapy, and stem cell platforms.
Younger mice demonstrate faster wound healing due to a more robust senescent cell response, while the accumulation of senescent cells with age paradoxically impairs regeneration. This reveals a temporal window in which senescent cell activation supports tissue repair before becoming detrimental.
Cleveland Clinic's awarded research uses redox biology—specifically NAD and NADH measurement—to assess metabolic viability of donor organs during the ischemic period before transplantation. This work translates longevity science concepts into actionable clinical tools for organ quality assessment and transplant outcomes.
